These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11084391)

  • 21. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
    Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CV 205-502 treatment of macroprolactinomas.
    Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
    Vilar L; Burke CW
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):821-6. PubMed ID: 7889620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
    Melkersson K; Hulting AL
    Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):6-10. PubMed ID: 10738858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
    Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
    Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
    Jaspers C; Benker G; Reinwein D
    Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
    Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR imaging of pituitary adenomas treated with the prolactin inhibitor quinagolide.
    Ilkko E; Tikkakoski T; Salmela P; Pyhtinen J; Kurunlahti M
    Acta Radiol; 2002 Mar; 43(2):125-9. PubMed ID: 12010287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolactinomas and resistance to dopamine agonists.
    Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
    Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
    Koloszár S; Keresztúri A; Kovács L
    Orv Hetil; 2000 Jul; 141(29):1621-3. PubMed ID: 10962898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.